Mostrar el registro sencillo del ítem

Artículo

dc.creatorRodríguez-Núñez, Pabloes
dc.creatorRomero Pérez, Lauraes
dc.creatorAmaral, Ana T.es
dc.creatorPuerto-Camacho, Pilares
dc.creatorJordán, Carmenes
dc.creatorMarcilla, Davides
dc.creatorÁlava Casado, Enrique dees
dc.creatorDíaz-Martín, Juanes
dc.date.accessioned2023-06-14T12:16:25Z
dc.date.available2023-06-14T12:16:25Z
dc.date.issued2020
dc.identifier.citationRodríguez-Núñez, P., Romero Pérez, L., Amaral, A.T., Puerto-Camacho, P., Jordán, C., Marcilla, D.,...,Díaz-Martín, J. (2020). Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma. The Journal of Pathology, 250 (4), 374-386. https://doi.org/10.1002/path.5379.
dc.identifier.issn0022-3417es
dc.identifier.issn1096-9896 (Electrónica)es
dc.identifier.urihttps://hdl.handle.net/11441/147210
dc.description.abstractYAP1 and TAZ (WWTR1) oncoproteins are thefinal transducers of the Hippo tumor suppressor pathway. Deregula-tion of the pathway leads to YAP1/TAZ activation fostering tumorigenesis in multiple malignant tumor types, includ-ing sarcoma. However, oncogenic mutations within the core components of the Hippo pathway are uncommon.Ewing sarcoma (EwS), a pediatric cancer with low mutation rate, is characterized by a canonical fusion involvingthe geneEWSR1andFLI1as the most common partner. The fusion protein is a potent driver of oncogenesis, but sec-ondary alterations are scarce, and little is known about other biological factors that determine the risk of relapse orprogression. We have observed YAP1/TAZ expression and transcriptional activity in EwS cell lines. Analyses of 55 pri-mary human EwS samples revealed that high YAP1/TAZ expression was associated with progression of the diseaseand predicted poorer outcome. We did not observe recurrent SNV or copy number gains/losses in Hippo pathway-related loci. However, differential CpG methylation of theRASSF1locus (a regulator of the Hippo pathway) wasobserved in EwS cell lines compared with mesenchymal stem cells, the putative cell of origin of EwS. Hypermethyla-tion ofRASSF1correlated with the transcriptional silencing of the tumor suppressor isoformRASFF1A, and tran-scriptional activation of the pro-tumorigenic isoformRASSF1C, which promotes YAP1/TAZ activation. Knockdownof YAP1/TAZ decreased proliferation and invasion abilities of EwS cells and revealed that YAP1/TAZ transcriptionactivity is inversely correlated with the EWS–FLI1 transcriptional signature. This transcriptional antagonism couldbe explained partly by EWS–FLI1-mediated transcriptional repression of TAZ. Thus, YAP1/TAZ may override the tran-scriptional program induced by the fusion protein, contributing to the phenotypic plasticity determined by dynamicfluctuation of the fusion protein, a recently proposed model for disease dissemination in EwSes
dc.formatapplication/pdfes
dc.format.extent13 pág.es
dc.language.isoenges
dc.publisherWileyes
dc.relation.ispartofThe Journal of Pathology, 250 (4), 374-386.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEwing sarcomaes
dc.subjectHippo pathwayes
dc.subjectMetastasises
dc.subjectImmunohistochemistryes
dc.subjectTranscriptional signatureses
dc.titleHippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcomaes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológicaes
dc.relation.projectIDGCB13-1578es
dc.relation.projectIDTPY-M 1149/13; TRPV 205/18es
dc.relation.projectIDGCB13-1578es
dc.relation.projectIDCB16/12/00361es
dc.relation.projectIDDKH-70112257es
dc.relation.projectIDPT17/0015/0041es
dc.relation.projectIDPI16CIII/00026; DTS18CIII/00005es
dc.relation.projectIDPI14/01466; PI17/00464es
dc.relation.publisherversionhttps://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.5379es
dc.identifier.doi10.1002/path.5379es
dc.journaltitleThe Journal of Pathologyes
dc.publication.volumen250es
dc.publication.issue4es
dc.publication.initialPage374es
dc.publication.endPage386es
dc.contributor.funderAsociacion Española Contra el Cancer (AECC)es
dc.contributor.funderAsociacion Pablo Ugartees
dc.contributor.funderAECC projectes
dc.contributor.funderCIBERONCes
dc.contributor.funderFundacion Publica Andaluza Progreso y Salud (Junta de Andalucia)es
dc.contributor.funderGerman Cancer Aides
dc.contributor.funderHospital Universitario Virgen del Rocio-Instituto de Biomedicina de Sevilla Biobank (ISCIII-Red de Biobancos)es
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderISCIII-FEDERes

FicherosTamañoFormatoVerDescripción
Hippo pathway effectors.pdf3.102MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional